Low-dose erythropoietin aggravates endotoxin-induced organ damage in conscious rats

Cytokine

Volumn 49, Issue 2, 2010, Pages 155-162

  Wu, Wen Tien ^a,b   Hu, Tsung Ming ^a,c   Lin, Nien Tsung ^a   Subeq, Yi Maun ^a   Lee, Ru Ping ^a   Hsu, Bang Gee ^a,b  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c Department of Psychiatry   (Taiwan)

Author keywords

Endotoxin shock; Erythropoietin; Pro inflammatory Cytokines

Indexed keywords

ERYTHROPOIETIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONSCIOUSNESS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; HEART RATE; INTESTINE INJURY; KIDNEY INJURY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER INJURY; LOW DRUG DOSE; LUNG INJURY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SEPTIC SHOCK; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ENDOTOXINS; ERYTHROPOIETIN; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTESTINE, SMALL; KIDNEY; LIPOPOLYSACCHARIDES; LIVER; LUNG; MALE; RANDOM ALLOCATION; RATS; RATS, INBRED WKY; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

ESCHERICHIA COLI; RATTUS;

EID: 73649136779     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.11.002     Document Type: Article

References (33)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., and Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 (2001) 1303-1310
2. Mayeux P.R. Pathobiology of lipopolysaccharide. J Toxicol Environ Health 51 (1997) 415-435
3. Haveman J.W., Muller Kobold A.C., Tervaert J.W., van den Berg A.P., Tulleken J.E., Kallenberg C.G., et al. The central role of monocytes in the pathogenesis of sepsis: consequences for immunomonitoring and treatment. Neth J Med 55 (1999) 132-141
4. Oberholzer A., Oberholzer C., and Moldawer L.L. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16 (2001) 83-96
5. Konstantinopoulos P.A., Karamouzis M.V., and Papavassiliou A.G. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin. Biochim Biophys Acta 1776 (2007) 1-9
6. Sharples E.J., Thiemermann C., and Yaqoob M.M. Mechanisms of disease: cell death in acute renal failure and emerging evidence for a protective role of erythropoietin. Nat Clin Pract Nephrol 1 (2005) 87-97
7. Cuzzocrea S., Di Paola R., Mazzon E., Patel N.S., Genovese T., Muià C., Crisafulli C., et al. Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 34 (2006) 1168-1177
8. Aoshiba K., Onizawa S., Tsuji T., and Nagai A. Therapeutic effects of erythropoietin in murine models of endotoxin shock. Crit Care Med 37 (2009) 889-898
9. Abdelrahman M., Sharples E.J., McDonald M.C., Collin M., Patel N.S., Yaqoob M.M., et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 22 (2004) 63-69
10. Hojman P., Taudorf S., Lundby C., and Pedersen B.K. Erythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans. Cytokine 45 (2009) 154-157
11. Hsu B.G., Yang F.L., Lee R.P., Peng T.C., and Chen H.I. Posttreatment with low dose propofol on inflammation responses to lipopolysaccharide-induced shock in conscious rats. Clin Exp Pharmacol Physiol 32 (2005) 24-29
12. Hsu B.G., Lee R.P., Yang F.L., Harn H.J., and Chen H.I. Post-treatment with N-acetylcysteine ameliorates the endotoxin shock-induced organ damage in conscious rats. Life Sci 79 (2006) 2010-2016
13. Chen C.H., Lee R.P., Wu W.T., Liao K.W., Hsu N., and Hsu B.G. Fluvastatin attenuate endotoxin shock induced organ damage in conscious rats. Resuscitation 74 (2007) 166-174
14. Lee C.J., Subeq Y.M., Lee R.P., and Hsu B.G. Low-dose propofol ameliorates hemorrhagic shock induced organ damage in conscious rats. Clin Exp Pharmacol Physiol 35 (2008) 766-774
15. Lee C.C., Lee R.P., Subeq Y.M., Lee C.J., Chen T.M., and Hsu B.G. Fluvastatin attenuates severe hemorrhagic shock-induced organ damage in rats. Resuscitation 80 (2009) 372-378
16. Ayala A., Lomas J.L., Grutkoski P.S., and Chung C.S. Pathological aspects of apoptosis in severe sepsis and shock?. Int J Biochem Cell Biol 35 (2003) 7-15
17. Klemm K., Eipel C., Cantré D., Abshagen K., Menger M.D., and Vollmar B. Multiple doses of erythropoietin impair liver regeneration by increasing TNF-alpha, the Bax to Bcl-xL ratio and apoptotic cell death. PLoS ONE 3 (2008) e3924
18. Kumral A., Baskin H., Yesilirmak D.C., Ergur B.U., Aykan S., Genc S., et al. Erythropoietin attenuates lipopolysaccharide-induced white matter injury in the neonatal rat brain. Neonatology 92 (2007) 269-278
19. Hitti E., Iakovleva T., Brook M., Deppenmeier S., Gruber A.D., Radzioch D., et al. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol 26 (2006) 2399-2407
20. Arbabi S., and Maier R.V. Mitogen-activated protein kinases. Crit Care Med 30 (2002) S74-S79
21. Nagata Y., Moriguchi T., Nishida E., and Todokoro K. Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3. Blood 90 (1997) 929-934
22. Riedemann N.C., Guo R.F., and Ward P.A. Novel strategies for the treatment of sepsis. Nat Med 9 (2003) 517-524
23. Schmeding M., Neumann U.P., Boas-Knoop S., Spinelli A., and Neuhaus P. Erythropoietin reduces ischemia-reperfusion injury in the rat liver. Eur Surg Res 39 (2007) 189-197
24. Bockhorn M., Fingas C.D., Rauen U., Canbay A., Sotiropoulos G.C., Frey U., et al. Erythropoietin treatment improves liver regeneration and survival in rat models of extended liver resection and living donor liver transplantation. Transplantation 86 (2008) 1578-1585
25. Johnson D.W., Forman C., and Vesey D.A. Novel renoprotective actions of erythropoietin: new uses for an old hormone. Nephrology 11 (2006) 306-312
26. Nemoto T., Yokota N., Keane W.F., and Rabb H. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int 59 (2001) 246-251
27. Mitra A., Bansal S., Wang W., Falk S., Zolty E., and Schrier R.W. Erythropoietin ameliorates renal dysfunction during endotoxaemia. Nephrol Dial Transplant 22 (2007) 2349-2353
28. Wu H., Ren B., Zhu J., Dong G., Xu B., Wang C., et al. Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. Eur J Cardiothorac Surg 29 (2006) 902-907
29. Wu H., Dong G., Liu H., Xu B., Li D., and Jing H. Erythropoietin attenuates ischemia-reperfusion induced lung injury by inhibiting tumor necrosis factor-alpha and matrix metalloproteinase-9 expression. Eur J Pharmacol 602 (2009) 406-412
30. Kim M.O., Kim S.H., Shin M.J., Lee D.B., Kim T.W., Kim K.S., et al. Human erythropoietin induces lung failure and erythrocytosis in transgenic mice. Mol Cells 23 (2007) 17-22
31. Mori S., Sawada T., Okada T., and Kubota K. Erythropoietin and its derivative protect the intestine from severe ischemia/reperfusion injury in the rat. Surgery 143 (2008) 556-565
32. Guneli E., Cavdar Z., Islekel H., Sarioglu S., Erbayraktar S., Kiray M., et al. Erythropoietin protects the intestine against ischemia/reperfusion injury in rats. Mol Med 13 (2007) 509-517
33. Vesey D.A., Cheung C., Pat B., Endre Z., Gobe G., and Johnson D.W. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 19 (2004) 348-355